Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) predict response to tyrosine kinase inhibitors. Mutations occur more …

Purpose Epidermal growth factor receptor (EGFR) mutations confer sensitivity to EGFR
tyrosine kinase inhibitors in patients with advanced non–small-cell lung cancer (NSCLC) …

Purpose Previous studies in non–small-cell lung cancer (NSCLC) have demonstrated a
wide variation in responsiveness to epidermal growth factor receptor (EGFR)–targeting …

The aim of the present study was to determine the prevalence of epidermal growth factor
receptor mutations (EGFRmut) in the Gulf region (GR) and its correlation with demographic …

BACKGROUND: The Medical Oncology Department at Tata Memorial Hospital, the single
largest tertiary cancer care center in Asia, receives in-house registered and referral patient …

Introduction Despite available data from other Asian countries, the prevalence of epidermal
growth factor receptor (EGFR) mutations among lung adenocarcinoma patients has not …

Introduction: Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung
cancer predict response to tyrosine kinase inhibitors. The frequency of EGFR mutations is …

Introduction: The detection of mutations in the epidermal growth factor receptor (EGFR)
gene, which predict sensitivity to treatment with EGFR tyrosine kinase inhibitors, represents …

Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to
EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The …

Introduction Previous exploratory analysis of epidermal growth factor receptor (EGFR)
mutational status in tumor samples from randomized clinical studies suggested that patients …